Supplementary Tables 1 Through 4 from AZD2014, an Inhibitor of Mtorc1 and Mtorc2, is Highly Effective in ER+ Breast Cancer when Administered Using Intermittent or Continuous Schedules

Supplementary table 1: Biochemical and cellular activity of AZD2014. Supplementary table 2: Biochemical activity of AZD2014. Supplementary table 3: Anti proliferative activity of AZD2014 in a panel of ER+, endocrine resistant and LTED cell lines. Supplementary table 4: Activity of AZD2014 in a number of ER+ breast cancer in vivo models.